



Singapore eDevelopment Names Biomedical Management Team That Includes Nobel Prize Nominee; Plans Research on Alzheimer's and Cancer

SINGAPORE, 13 March 2017 – Singapore-listed **Singapore eDevelopment Ltd (“SeD”)** announced the appointment today of its biomedical division’s senior management that will include a two-time Nobel Prize nominee, who will spearhead advanced research to develop a broad-spectrum therapeutic platform to address emerging pandemics such as Alzheimer’s, diabetes, cancer, drug-resistant viruses and antibiotic-resistant bacteria.

Mr Daryl Thompson, a biochemist nominated for the Nobel Prize in 2015 and 2016 for his research on pandemic technology, has been appointed Director of Scientific Initiatives as part of a six-member management team of SeD BioMedical Inc. (“SeD BioMedical”), which has offices in Singapore, Winter Haven, Florida, U.S. and Petaling Jaya, Malaysia.

SeD BioMedical was formed on 18 November 2016 as part of a strategic diversification by Singapore Exchange-listed SeD, to develop, research, manufacture and distribute biomedical products and services. SeD currently holds 80% of SeD BioMedical, with the balance held equally by Global Research and Discovery Group Scientific LLC (“GRDGS”) and Holista CollTech Limited (“Holista”), an Australia-listed company in which SeD BioMedical Chief Executive Officer Dr Rajen Manicka is Founder and Executive Chairman.

Mr Chan Heng Fai, Executive Director and Chief Executive Officer of SeD, said, “I am delighted to have Dr Rajen, Mr Thompson and the rest of the team on board SeD BioMedical. They bring deep expertise and industry knowledge in their respective fields and will be an asset to the Group as we diversify into the biomedical space.”

SeD BioMedical is formalising the assignment of the biomedical intellectual property held by GRDGS. This will include patents for its *Linebacker* platform, a natural-based universal therapeutic formula to treat and prevent pro-inflammatory derived disease.

SeD BioMedical will leverage on the existing research findings of *Linebacker*, which has established therapeutic efficacy against neurologic diseases, diabetes, and viruses including rhinovirus, influenza and Ebola.

Alzheimer’s, the most common form of dementia, is a progressive and irreversible neurodegenerative disease that causes problems with memory, thinking and behaviour. It affects millions of people worldwide. Ebola is a severe and often fatal viral disease transmitted from wild animals and through physical contact with infected human beings.

SeD BioMedical will build upon the existing research collaboration of GRDGS with Charles River Laboratories and their centres of excellence in Finland and Freiburg, Germany (formerly Oncotest GmbH) to research and carry out non-clinical testing of various biomedical products.

Dr Rajen said, “We have assembled a world-class team to work with some of the best research facilities in the United States and Europe. We feel confident that we will deliver a viable proof of concept for the formula by December this year.”

13 March 2017

Page 2 of 3

Mr Thompson said, "We have done all work with our models and on the natural compound. We feel confident that we will make this work in the patented molecule that we are now going to synthesise and test."

The management team of SeD BioMedical comprises:

- **Dr Rajen Manicka (Chief Executive Officer)** – Dr Rajen is a pharmacist by training. He has a doctorate in Holistic Medicine and also holds a Master's in Business Administration. He is the Founding Executive Chairman and Chief Executive Officer of Holista, a research-driven biotechnology company listed on the Australian Securities Exchange.
- **Mr Daryl L. Thompson (Director of Scientific Initiatives)** – Mr Thompson, a two-time Nobel Prize nominee, is a serial inventor and entrepreneur. He is the president of GRDGS and has successfully patented, developed and branded several products. These include a natural therapeutic for diabetes and obesity which buffers sugar in food and drinks, an anti-retroviral agent, a non-invasive blood glucose monitoring device, and a nutraceutical grapefruit-based compound that has been clinically documented to promote weight loss without the exercise component. Most recently, he has patented a product that can defend against neurological disease.
- **Mr Scott M. Truesdell (Research Coordinator)** – Mr Truesdell is a serial entrepreneur who served as an Intelligence Operator in the U.S. Marine Corps, Chief Information Officer for a mutual fund, and consultant to Fortune 500 companies. He has over 30 years' experience in leading large projects, data analysis, and integrating bleeding-edge technology positions him well to coordinate and execute the research and development of this platform.
- **Mr Lau Keng Yap, Kent (R&D Commercialisation)** – Mr Lau is a biotechnologist with a focus on commercialisation.

Shareholders and potential investors of the Company are hereby reminded to exercise caution when dealing in the securities of the Company. In particular, shareholders and potential investors of the Company are reminded that there is no assurance that any transactions mentioned in this announcement will materialise.

Persons who are in doubt to the action they should take should consult their stockbrokers, bank managers, solicitors or other professional advisors.

End of Release

Issued on behalf of the Company by WeR1 Consultants Pte Ltd:

Media & Investor Contact Information

WeR1 Consultants Pte Ltd
3 Phillip Street, #12-01, Royal Group Building
Singapore 048693
Tel: (65) 6737 4844
Ian Lau, ianlau@wer1.net

13 March 2017

Page 3 of 3

About Singapore eDevelopment Limited

Incorporated on 9 September 2009 and listed on the Singapore Exchange Catalist in July 2010, Singapore eDevelopment Limited is involved in (i) property development and investments primarily in the United States and Western Australia; (ii) Information Technology- related businesses; (iii) development, research, testing, manufacturing, licensing and distribution of biomedical products; and (iv) investment activities.

For more information, please visit: www.SeD.com.sg

This announcement has been prepared by the Company and its contents have been reviewed by the Company's Sponsor Hong Leong Finance Limited (the "Sponsor") for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited (the "SGX-ST"). The Sponsor has not independently verified the contents of this announcement.

This announcement has not been examined or approved by SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr Tang Yeng Yuen, Vice President, Head of Corporate Finance, Hong Leong Finance Limited, at 16 Raffles Quay, #40-01A Hong Leong Building, Singapore 048581, telephone: +65 6415-9886.